MEDS Company Profile and Key Details

MEDS has shown mixed momentum, gaining 3.14% over the past week and -17.03% over the past quarter, though year-to-date performance is up 45.3%. Short-term trend indicators are mixed aligned (SMA20 4.09%, SMA50 -20.21%, SMA200 3.6%). The stock’s 14-day RSI is 49.47 (neutral), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -72.66% below its high and over 230.18% above its low. Average 10-day trading volume of 246.43 thousand shares is significantly above the 3-month average of 162.17 thousand, indicating heightened recent market interest.

DataMEDS AI, Inc. has 2.51 million shares outstanding. The public float is 614.46 thousand shares, elevated short interest at 7.18% of float. This equals 105.20 thousand shares. The short ratio is 2.02 days. Institutional investors hold 18.07% of the float. Insiders own 61.7%. Patel Prashant holds 1.25 million shares, AJJARAPU SURENDRA K has 222.50 thousand shares and Fell Donald G. has 21.14 thousand shares.

DataMEDS AI, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 09, 2024, missed forecasts by 593.33%. The prior quarter beat by 4166.67%. Over the last six quarters, Apple has recorded several small beats. These include 500.0% in November 06, 2023.

DataMEDS AI, Inc. (NASDAQ:MEDS) closed at $1.44 USD, losing -$0.05 (-3.36%) from the previous close of $1.49. The stock is currently mid-range between its 52-week high and low $1.25 and $97.50. With a market capitalization of about $3.78 million, DataMEDS AI, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.52). Key stats such as the average daily volume over the past year has been around 328.93 thousand shares, volume is running light vs its 52-week average. Headquartered in Tampa, FL, DataMEDS AI, Inc. operates in the Healthcare sector and the Medical - Distribution industry. Led by CEO Prashant Patel, the company employs approximately 31 people and listed since February 21, 2025. DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

DataMEDS AI, Inc. trades at a P/E ratio of -0.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.49 and a price-to-book ratio of -0.2 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.29, also above market averages.

Our AI price prediction model suggests that DataMEDS AI, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.05%, with price expected at $1.37 by August 31, 2026, within a range of $0.80 to $1.97 3-Month Outlook: Projected fall of -73.15%, reaching $0.40 by November 13, 2026, with a range of $0.00 to $1.32. 1-Year Outlook: Projected loss of -93.29%, with price at $0.10 by August 17, 2027, within a range of $0.00 to $1.08.

DataMEDS AI, Inc. (NASDAQ:MEDS) shares are up 45.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows DataMEDS AI, Inc. trading at a premium to the broader market with a P/E of -0.03. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $1.42, suggesting -4.7% downside. Our AI forecast model points to short-term weakness (-8.05% over two weeks), a medium-term fall (-73.15% over three months), and a longer-term loss (-93.29% over one year), with expected trading ranges indicating moderate volatility.